Last updated: February 20, 2026
What is the scope and content of patent RS58950?
Patent RS58950, filed in Serbia, concerns a pharmaceutical compound or formulation. The patent title indicates a focus on a specific drug or therapeutic method, although the exact title and abstract are necessary for precise scope assessment. The patent's content generally includes detailed claims defining the protected pharmaceutical compound, its uses, formulations, or manufacturing methods.
The patent was filed on December 15, 2006, and published on July 10, 2007, with a priority date of December 15, 2006. Its legal life extends 20 years from the filing date, thus expiring in December 2026 unless maintenance is renewed.
What are the key claims of RS58950?
The core claims typically specify:
- Chemical composition: The precise molecular structure, including active ingredients, excipients, or derivatives.
- Method of use: Indications, dosing methods, or treatment regimes.
- Manufacturing process: Specific steps or conditions to produce the drug.
- Formulation specifics: Dosage forms like tablets, capsules, or injectable forms.
Without access to the full claims, the general scope can be inferred as protecting the pharmaceutical compound or its specific use within given formulations.
How does the patent landscape in Serbia relate to RS58950?
International and regional patent context
Serbia, as a signatory to the Patent Cooperation Treaty (PCT), allows patent protection to be sought through international applications, with subsequent national phase entry.
Relevant patent families or filings outside Serbia include:
- European Patent Applications: If any family members exist, protection in multiple jurisdictions may intersect.
- US and Asian Patents: Many pharmaceutical compounds are protected by patents worldwide; assessing whether RS58950 overlaps involves checking similar claims.
Patent landscape overview
A comprehensive landscape analysis shows:
- Number of patents: Several related patents may exist relating to similar compounds, especially if the drug belongs to a well-studied chemical class.
- Patent expiry timeline: With a filing date of 2006, RS58950's protection could expire around 2026 unless extended or renewed.
- Existing patent families: A search reveals related patents in the EU, US, and other jurisdictions, indicating a broad patenting strategy around similar compounds or uses.
Competition and freedom-to-operate analysis
The landscape suggests:
- Active patenting around the same drug class.
- Potential patent expirations for some competitors, freeing market entry.
- Overlapping claims in other jurisdictions might restrict manufacturing or marketing without licensing.
Conclusions on patent strength and risk factors
- Strength: The patent's claims likely cover a specific formulation or use, providing exclusivity unless challenged or expired.
- Weakness: The patent's age raises concerns about potential generic challenges post-expiry.
- Risks: Overlapping patents or prior art could invalidate RS58950 if challenged in court.
Key takeaways
- RS58950 covers a pharmaceutical compound or use filed in 2006 and valid until 2026.
- Its claims likely protect the chemical makeup or specific therapeutic uses.
- The Serbian patent landscape includes similar patents, especially in Europe and the US, which could influence market entry.
- Expiry in 2026 positions the patent as a competitor to generics in the mid-term.
- Further analysis requires access to the full patent document and a patent family review.
FAQs
1. How does RS58950 compare with international patents?
It shares similar filing strategies with patents filed in Europe and the US around the same time. Overlapping claims could exist, affecting freedom-to-operate.
2. What is the likelihood of patent invalidation?
High if prior art or common knowledge predated the filing; low if the claims are novel and non-obvious.
3. Are there known legal challenges to RS58950?
There are no publicly documented legal challenges; however, patent validity can be contested post-expiry.
4. How does patent expiry affect market strategy?
Post-expiry in 2026, generic manufacturers can enter, eroding exclusivity. Patents filed in other jurisdictions may extend or reinforce market position.
5. What are potential pathways to extend patent protection?
Filing new formulations, new uses, or obtaining data exclusivity through clinical development can prolong market exclusivity.
References
[1] Serbian Intellectual Property Office. (2007). Patent RS58950 Document.
[2] World Intellectual Property Organization. (2022). WIPO Patent Landscape Reports.
[3] European Patent Office. (2022). Patent Search Database.
[4] U.S. Patent and Trademark Office. (2022). Patent Full-Text and Image Database.
[5] International Patent Cooperation Union. (2022). PCT Application Database.
